Save Ceftolozane/Tazobactam for Resistant E. coli or Pseudomonas

March 2015

Please see the FDA safety warning (May 2015) concerning dose confusion/medication errors associated with Zerbaxa

Reps will be promoting a new IV anti-infective, ceftolozane/tazobactam (Zerbaxa).

It's approved for complicated UTIs (cUTIs) and intra-abdominal infections (cIAIs) in adults. And higher doses are also being studied for ventilator-associated pneumonia.

Ceftolozane/tazobactam primarily covers gram-negative bacteria...including Pseudomonas and ESBL-producing Enterobacteriaceae.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote